BARALDI, Pier Giovanni
 Distribuzione geografica
Continente #
NA - Nord America 28.293
EU - Europa 8.985
AS - Asia 5.687
SA - Sud America 42
AF - Africa 31
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 27
Totale 43.095
Nazione #
US - Stati Uniti d'America 28.249
CN - Cina 3.159
DE - Germania 2.665
UA - Ucraina 2.238
TR - Turchia 1.691
GB - Regno Unito 955
IT - Italia 897
SE - Svezia 801
FI - Finlandia 483
SG - Singapore 482
RU - Federazione Russa 436
FR - Francia 158
VN - Vietnam 117
PL - Polonia 114
BE - Belgio 59
NL - Olanda 55
IN - India 47
CZ - Repubblica Ceca 37
HK - Hong Kong 36
KR - Corea 31
CA - Canada 28
JP - Giappone 27
EU - Europa 24
AU - Australia 23
IR - Iran 22
MA - Marocco 21
TW - Taiwan 19
CL - Cile 18
IL - Israele 16
MX - Messico 16
BR - Brasile 10
ID - Indonesia 10
RO - Romania 10
CO - Colombia 9
AT - Austria 8
CH - Svizzera 8
HU - Ungheria 8
IE - Irlanda 7
MY - Malesia 7
NO - Norvegia 7
NZ - Nuova Zelanda 7
ES - Italia 6
PK - Pakistan 6
ZA - Sudafrica 6
PT - Portogallo 5
BG - Bulgaria 4
GR - Grecia 4
IQ - Iraq 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
BD - Bangladesh 3
EG - Egitto 3
HR - Croazia 3
LT - Lituania 3
MD - Moldavia 3
DK - Danimarca 2
LU - Lussemburgo 2
PS - Palestinian Territory 2
SI - Slovenia 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
EC - Ecuador 1
IM - Isola di Man 1
KH - Cambogia 1
LK - Sri Lanka 1
MC - Monaco 1
ME - Montenegro 1
MN - Mongolia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 43.095
Città #
Woodbridge 3.792
Fairfield 3.594
Jacksonville 2.451
Houston 2.445
Chandler 2.077
Ashburn 2.033
Ann Arbor 1.914
Seattle 1.499
Wilmington 1.382
Cambridge 1.093
Izmir 799
Nanjing 771
Beijing 542
Princeton 512
Boardman 399
San Diego 322
Singapore 290
Shenyang 266
Ferrara 261
Nanchang 213
Milan 202
Shanghai 198
Hebei 158
New York 154
San Mateo 154
Bremen 144
Addison 142
Tianjin 141
Changsha 139
Jiaxing 122
Dearborn 114
Dong Ket 114
Jinan 106
Warsaw 104
Philadelphia 88
Falls Church 86
Norwalk 83
Redwood City 78
Kunming 76
Zhengzhou 70
Mountain View 59
Brussels 58
London 57
Ningbo 50
Auburn Hills 47
Orange 47
Guangzhou 44
Verona 43
Los Angeles 39
Amsterdam 37
Des Moines 37
Indiana 37
Munich 35
Taizhou 34
Lanzhou 32
Hong Kong 28
Tappahannock 28
Hangzhou 27
Chicago 26
Paris 25
Washington 25
Helsinki 24
Düsseldorf 22
Mcallen 22
Redmond 22
Augusta 20
Haikou 20
Montréal 20
Brno 19
Taipei 19
Duncan 15
Leawood 15
Hefei 14
Kilburn 14
San Francisco 14
Xian 13
Bari 12
Monmouth Junction 12
Fuzhou 11
Olomouc 11
Rome 11
Yellow Springs 11
Ardabil 10
Marrakesh 10
Chiswick 9
Corvallis 9
Taiyuan 9
Weihai 9
Bologna 8
Padova 8
Palo Alto 8
Changchun 7
Dublin 7
Prescot 7
Acton 6
Budapest 6
Hounslow 6
Medellín 6
Moscow 6
Mumbai 6
Totale 30.421
Nome #
[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1 354
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists 312
1,4-Diketones via Isoxazole Intermediates 294
1,2,3-triazolo[5,4-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new class of A(2A) adenosine receptor antagonists 268
null 227
A glance at adenosine receptors: Novel target for antitumor therapy 193
1-methyl-3-nitro-5-methoxycarbonyl pyrazole 162
The A3 adenosine receptor: history and perspectives 160
A new, efficient synthesis of muscimol (5-ammoniomethylisoxazol-3-olate). 156
A synthetic approach for the preparation of rigid analogs of 1,3-dipropyl-7-methyl-8-aryl/heteroarylstyryl xanthines 152
Synthesis and Structure Activity Relationship Investigation of Triazolo[1,5-a]pyrimidines as CB2 Cannabinoid Receptor Inverse Agonists 151
Azaprostaglandin Analogues. Synthesis and Biological Properties of 11-Azaprostaglandin Derivatives 149
A facile, efficient synthesis of 2-substituted-4-hydroxy-2-cyclopenten-1-ones 149
Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor 149
Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility 147
Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists 146
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 145
Geiparvarin analogs. 2. Synthesis and cytostatic activity of 5-(4-arylbutadienyl)-3(2H)-furanones and of N-substituted 3-(4-oxo-2-furanyl)-2-buten-2-yl carbamates. 142
Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety 142
3,5-Disubstituted isoxazoles as a latent aldol moiety: application to the synthesis of (±)-[6]-gingerol. 141
Active γ-manganese dioxide promoted conversion of 4,5-dihydro-1,2-oxazoles to 1,2-oxazoles. 141
Methyl 4-oxothiolane-3-carboxylate and methyl 2-methyl-4-oxothiolane-3- carboxylate anions as synthetic equivalents of α-acrylate and α-crotonate anions. Formal synthesis of integerrinecic acid 140
Design, Synthesis, DNA Binding, and Biological Evaluation of Water-Soluble Hybrid Molecules Containing Two Pyrazole Analogues of the Alkylating Cyclopropylpyrroloindole (CPI) Subunit of the Antitumor Agent CC-1065 and Polypyrrole Minor Groove Binders. 140
History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents 140
Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation 140
Ethyl 2,4-dioxoalkanoates as starting materials for a convenient route to 3(2H)-furanones and 3(2H)-furanimines 139
Geiparvarin Analogs. 3. Synthesis and cytostatic activity of 3(2H)-furanone and 4,5-dihydro-3(2H)-furanone congeners of geiparvarin, containing a geraniol-like fragment in the side chain 139
A [3+2] nitrile oxide intermolecular cycloaddition approach to 4,5-dihydro-3(2H)-furanone and 3(2H)-furanone ring systems: application to the formal synthesis of (±)-ascofuranone and geiparvarin. 139
Synthesis and biological evaluation of 2-and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization 138
Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata 138
Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin 138
Synthesis and preliminary biological evaluation of new anti-tubulin agents containing different benzoheterocycles 137
Adenosine receptors and human melanoma 137
Current status of A1 adenosine receptor allosteric enhancers 137
Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents 137
3,5-Disubstituted isoxazoles as synthons for (±)-pyrenophorin and (±)-vermiculine synthesis. 136
Design, synthesis and in vitro cytotoxicity of a cis-dichloroplatinum(II) complex linked to the minor groove binder stallimycin 136
Geiparvarin Analogs. 4.1. Synthesis and Cytostatic Activity of Geiparvarin Analogs Bearing a Carbamate Moiety or a Furocoumarin Fragment on the Alkenyl Side Chain 135
2-Arylamino-4-Amino-5-Aroylthiazoles. "One-Pot" Synthesis and Biological Evaluation of a New Class of Inhibitors of Tubulin Polymerization. 135
Synthesis, in vitro antiproliferative activity, and DNA-binding properties of hybrid molecules containing pyrrolo[2,1-c][1,4] benzodiazepine and minor-groove-binding oligopyrrole carriers 135
Design, synthesis and growth inhibition activity of bis-epoxyethyl derivatives of stallimycin modified on the amidino moiety 133
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2. 133
A formal total synthesis (±)-forskolin through [3+2] nitrile oxide cycloaddition chemistry 133
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 133
Water-Soluble Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as Human A3 Adenosine Receptor Antagonists 132
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor 132
Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3’,4’,5’-Trimethoxyphenyl)-2-Aryl-1H-Imidazole 132
A [3 + 2] nitrile oxide cycloaddition approach to retinoids 131
DNA minor groove binders as potential antitumor and antimicrobial agents 131
Discovery and Optimization of a Series of 2-Aryl-4-Amino-5-(3 ',4 ',5 '-trimethoxybenzoyl)Thiazoles as Novel Anticancer Agents 131
New 2-heterocyclyl-imidazo[2,1- i ]purin-5-one derivatives as potent and selective human A 3 adenosine receptor antagonists 131
Synthesis of a new series of pyrazolo[1,5-a]pyrimidines structurally related to zaleplon 130
Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor 130
Design, synthesis and antiproliferative activity of novel heterobivalent hybrids based on imidazo[2,1-b][1,3,4]thiadiazole and imidazo[2,1-b][1,3]thiazole scaffolds 130
2,3a,5,6,7,7a-Hexahydro-3H,4H-benzothiophene-3,4-dione and cyclopenta[b]tetrahydrothiophene-3,4-dione enolate anions as synthetic equivalents to cyclohex-2-enone and cyclopent-2-enone C-2-carbanions. 129
From tyrosine to glycine: Synthesis and biological activity of potent antagonists of the purinergic P2X(7) receptor 129
Synthesis of hybrid distamycin-cysteine labeled with 99mTc: a model for a novel class of cancer imaging agents 129
A convenient synthesis of unsymmetrically substituted terphenyls of biologically active stilbenes via a double Suzuki cross-coupling protocol 129
Hybrid molecules based on distamycin A as potential antitumor agents 128
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. 127
Allosteric modulators for the A1-adenosine receptor 127
Novel 8-heterocyclyl xanthine derivatives in drug development - An update 127
Synthesis of 2-(5-substituted isoxazol-3-yl)-4-oxo-3-thiazolidinyl alkanoic acids 126
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH) 126
7-Substituted-pyrrolo[3,2-d]pyrimidine-2,4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: A promising approach for treating pain and inflammation 125
A new nitrile oxide based synthesis of the antitumor agent geiparvarin 124
Total synthesis of (±)-isoclovene. 124
1H-pyrazolo[2,3-d][1,2,4]triazine-3,7-diones as a new class of human leukocyte elastase inhibitors 124
New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2. 124
Design, synthesis and biological evaluation of 3-substituted-2-oxindole hybrid derivatives as novel anticancer agents 124
Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[(4- arylpiperazin-1-yl)methyl]-5-substituted-thiophenes. Effect of the 5-modification on allosteric enhancer activity at the A1 adenosine receptor 124
A new direct glycosylation of pyrimidine, pyrazole, imidazole and purine heterocycles via their N-tetrahydropyranyl (THP) derivatives 124
Synthesis and biological evaluation of 2-(3 ',4 ',5 '-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors 123
Pyrazolo [4,3-e][1,2,4]triazolo[1,5-c]pyrimidine template: Organic and medicinal chemistry approach 122
Synthesis and antitumor activity of novel distamycin derivatives 122
Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxyphenylsulfonyl)-5-aryl thiophenes as a new class of antitubulin agents 122
Synthesis of syn- and anti-tricyclo[4.1.0.02,4]heptan-5-ones and related compounds. 121
null 121
Recent improvements in the development of A2B adenosine receptor agonists. 121
null 121
Synthesis of 6‐substituted‐4,5‐dihydro‐3(2H)‐pyridazinones 120
Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c]pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists 120
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 120
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 120
Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D 1 or D2 dopamine receptor agonists 120
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists 120
A3 adenosine receptor antagonists: History and future perspectives 120
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors 120
null 120
Synthesis and cytotoxic activity of 6-vinyl- and 6-ethynyluridine and 8-vinyl- and 8-ethynyladenosine 119
Pyrazole-Related Nucleosides. Synthesis and Antiviral/Antitumor Activity of Some Substituted Pyrazole and Pyrazolo[4,3-d]-1,2,3-triazin-4-one Nucleosides 118
null 118
N-arylpiperazine modified analogues of the P2X(7) receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts 117
A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study 117
Allosteric Modulators of the A1 Adenosine receptor 117
Bis-epoxyethyl derivatives of distamycin A modified on the amidino moiety: Induction of production of fetal hemoglobin in human erythroid precursor cells 117
Preparation of 3,4-dihydroxy-1-benzeneethanol: a reinvestigation 116
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A2A receptor antagonists. 116
Sintesi di derivati pirazolici e pirazolo[4,3-d]pirimidonici. Nota I 116
A new simple synthesis of a-substituted acrylonitriles 116
Totale 13.948
Categoria #
all - tutte 158.083
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.546
Totale 159.629


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.848 1.601 282 278 1.280 575 1.001 704 875 643 1.046 409 154
2020/20216.321 641 592 270 697 298 649 146 728 122 786 837 555
2021/20225.107 159 470 374 291 374 252 208 244 198 362 528 1.647
2022/20234.812 509 249 108 647 884 775 145 392 614 31 286 172
2023/20242.417 243 309 129 82 170 287 95 398 28 60 56 560
2024/2025165 165 0 0 0 0 0 0 0 0 0 0 0
Totale 43.565